Showing results (471-480 of 19,457) with videos related to

Sort By:
Pageof 1,946
Lancet (London, England)|April 9, 2019
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony S K Mok, Yi-Long Wu, Iveta Kudaba, et al.
Lancet (London, England)|March 17, 2019
Trends in cause-specific mortality among children aged 5-14 years from 2005 to 2016 in India, China, Brazil, and Mexico: an analysis of nationally representative mortality studiesShaza A Fadel, Cynthia Boschi-Pinto, Shicheng Yu, et al.
Lancet (London, England)|September 10, 2019
PemphigusEnno Schmidt, Michael Kasperkiewicz, Pascal Joly
Lancet (London, England)|September 20, 2019
Advances in β-cell replacement therapy for the treatment of type 1 diabetesMarie-Christine Vantyghem, Eelco J P de Koning, François Pattou, et al.
Lancet (London, England)|September 20, 2019
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialRajiv Agarwal, Patrick Rossignol, Alain Romero, et al.
Lancet (London, England)|September 20, 2019
Advances in technology for management of type 1 diabetesRoy W Beck, Richard M Bergenstal, Lori M Laffel, et al.
Lancet (London, England)|September 23, 2019
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trialDavid R Matthews, Päivi M Paldánius, Pieter Proot, et al.
Lancet (London, England)|October 5, 2019
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trialsJohann Christian Virchow, Piotr Kuna, Pierluigi Paggiaro, et al.
Lancet (London, England)|October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLuis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
Lancet (London, England)|June 14, 2024
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trialTimothy L Jackson, Riti Desai, Hatem A Wafa, et al.
Pageof 1,946